3 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
Follow Refractory Osteosarcoma: new trials by email Literature Review of Refractory Osteosarcoma trials Research Report on Refractory Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cabozantinib With Topotecan-Cyclophosphamide Cabozantinib, Topotecan, Cyclophosphamide - Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 12 | 2020-12-23 | 2023-02-15 |
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 26 | 2018-01-31 | 2024-07-15 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
Osteosarcoma (3) · Hodgkin Disease (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Neuroblastoma (1) · Neuroectodermal Tumors, Primitive, Peripheral (1) · Rhabdomyosarcoma (1) · Sarcoma, Ewing (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Bone Tissue (3) · Neoplasms, Connective Tissue (3) · Neoplasms, Connective and Soft Tissue (3) · Sarcoma (3) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoproliferative Disorders (1) · Myosarcoma (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1)
CTLA-4 Antigen (1) · Cyclophosphamide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Ipilimumab (1) · Nivolumab (1) · Topotecan (1) · cabozantinib (1) · pegfilgrastim (1) · pepinemab (1)
Children's Oncology Group (1) · Dana-Farber Cancer Institute (1) · National Cancer Institute (NCI) (1)
United States (3) · Canada (1)
Crystal L Mackall (1) · Emily G Greengard (1) · Steven C DuBois, MD (1)
PMID 31401903, PMID 32192573, PMID 38520670
UM1CA097452 (2)